Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

mellerud chemie gmbh, bernhard röttgen-waldweg 20, de-41379 brüggen (vokietija). - 2-oktil-2h-izotiazol-3-onas - veikliosios medžiagos cas nr.: 26530-20-1, eb nr.: 247-761-7, veikliosios medžiagos pavadinimas: 2-oktil-2h-izotiazol-3-onas, koncentracija: 0.32% , veiklioji - statybinių medžiagų konservantai

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

lonza cologne gmbh, nettermannallee 1, de-50829 cologne (vokietija - cinko piritionas - veikliosios medžiagos cas nr.: 13463-41-7, eb nr.: 236-671-3, veikliosios medžiagos pavadinimas: cinko piritionas, koncentracija: 38.8% , veiklioji - statybinių medžiagų konservantai

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

mellerud chemie gmbh, bernhard röttgen-waldweg 20, de-41379 brüggen (vokietija). - 2-oktil-2h-izotiazol-3-onas - veikliosios medžiagos cas nr.: 26530-20-1, eb nr.: 247-761-7, veikliosios medžiagos pavadinimas: 2-oktil-2h-izotiazol-3-onas, koncentracija: 0.32% , veiklioji - statybinių medžiagų konservantai

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritas, reumatas - imunosupresantai - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriazė - imunosupresantai - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

tad pharma gmbh - atorvastatinas - plėvele dengtos tabletės - 20 mg; 10 mg; 40 mg - atorvastatin

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

csl behring gmbh - žmogaus normalus imunoglobulinas (scig) - imunologinių trūkumų sindromai - imuninės serumai ir imunoglobulinai, - replacement therapy in adults, children and adolescents (0-18 years) in:- primary immunodeficiency syndromes with impaired antibody production (see section 4. - secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumabas - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imunosupresantai - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - kiti nervų sistemos vaistai - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

lonza cologne gmbh, nattermannallee 1 50829 cologne (vokietija). - granuliuotas varis; granuliuotas varis; granuliuotas varis - veikliosios medžiagos cas nr.: -, eb nr.: -, veikliosios medžiagos pavadinimas: granuliuotas varis, koncentracija: 9% , veiklioji; veikliosios medžiagos cas nr.: -, eb nr.: -, veikliosios medžiagos pavadinimas: granuliuotas varis, koncentracija: 9% , veiklioji; veikliosios medžiagos cas nr.: -, eb nr.: -, veikliosios medžiagos pavadinimas: granuliuotas varis, koncentracija: 9% , veiklioji - medienos konservantai